Parkinsonism Clinical Trial
Official title:
Ultrasound Changes of the Vagus Nerve in Patients With Parkinsonism
In this study, the investigators will assess the Vagus nerve in two groups: Group 1 which include patients with parkinsonism and group 2 which included age and sex matched healthy control. The aim of the study is: detecting the difference between both groups and correlating the changes in the Vagus nerve cross sectional area with the motor and non motor manifestations of parkinsonism
Parkinsonism is a syndrome characterized by the presence of six cardinal motor characteristics: resting tremor, rigidity, bradykinesia, loss of postural reflexes, flexed posture, and freezing. These combined symptoms identify clinically definite, probable, and possible parkinsonism (1). The most common form of parkinsonism is Parkinson's disease (PD) (1). Other forms of parkinsonism included atypical parkinsonism as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal syndrome (CBS). The former types of parkinsonism are neurodegenerative disorders. Vascular parkinsonism (VP) is another form attributed to vascular etiology (2). PD is the second-most common neurodegenerative disorder that affects 2-3% of the population ≥65 years of age. The main manifestation of PD is a clinical hypokinetic rigid syndrome. Also, numerous non-motor symptoms (NMS), including autonomic symptoms, such as orthostatic hypotension, constipation and urinary incontinence, have been suggested as preclinical symptoms (3). Other NMS include sleep alterations, dementia, depression, and pain that may severely compromise the quality of life (4). The main neuropathologic hallmark is the formation of cytoplasmic inclusions called α-synuclein-enriched Lewy bodies and Lewy neurites. These aggregations are found throughout the brain, most pronounced in the substantia nigra compacta (5, 6). Also, these aggregations are present in the peripheral nervous system, more specifically in the Vagus nerve, which plays a vital role in autonomic control (7, 8). In addition, the Vagus nerve may play a crucial role in PD pathogenesis as it was hypothesized that α-synuclein aggregates form in the enteric nervous system and spread to the CNS via the autonomic nervous system (9). Neuromuscular ultrasound is a non-invasive tool that can visualize nerves and roots with high resolution and accuracy (10). A recent systematic review reported that in PD, there is a degree of Vagus nerve atrophy that may be detected by ultrasound; therefore, it can be utilized as a marker for Vagus nerve lesions. However, correlation studies are lacking between the findings and clinical manifestations of parkinsonism (11). Several studies were conducted to examine vagal neuron loss by ultrasonography, but they reported contradictory results. For example, some studies discovered considerable atrophy of the Vagus nerves in PD patients (12-15). However, other studies found no difference between PD patients and healthy controls (16-19). In addition, the link between Vagus nerve atrophy and other atypical parkinsonism, MSA, PSP, and CBS has not been extensively studied (20). The present study aims to detect ultrasound changes in the Vagus nerve in patients with parkinsonism, compare the findings with healthy control, and correlate these changes with the motor and non-motor manifestations. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
Active, not recruiting |
NCT05127057 -
Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT)
|
N/A | |
Enrolling by invitation |
NCT01453127 -
DaTSCAN Imaging in Aging and Neurodegenerative Disease
|
Phase 4 | |
Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
Completed |
NCT03314610 -
Effect of Need to Void on Parkinsonian Gait
|
||
Recruiting |
NCT05506891 -
Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy
|
Phase 2 | |
Completed |
NCT00950196 -
Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
|
Phase 4 | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Enrolling by invitation |
NCT05514106 -
MIBG in Aging and Neurologic Disorders
|
Phase 4 | |
Completed |
NCT01581645 -
Mobilaser Study to Help With People Who Are Having Problems With Their Gait
|
Phase 0 | |
Not yet recruiting |
NCT00767546 -
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
|
Phase 1 | |
Completed |
NCT02214862 -
2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
|
Phase 0 | |
Recruiting |
NCT04518059 -
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
|
||
Completed |
NCT03076671 -
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
|
N/A | |
Withdrawn |
NCT01329926 -
Molecular Analysis of Human Neural Stem Cells
|
||
Terminated |
NCT00745030 -
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
|
N/A | |
Completed |
NCT04222218 -
Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT03386669 -
Novel Neuroimage Study in Tauopathies With Parkinsonism
|
Phase 2 | |
Completed |
NCT02064543 -
Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism
|